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pathogens within the female genital tract. Vitamin D deficiency also puts pregnant women at higher risk for preterm birth, 6, 7 preeclampsia, 8 gestational diabetes, as well as delivery of a small-for-gestational age neonate. 8, 9 While optimal supplementation dosing has not been firmly established, prior trials suggest optimal conversion to the active form of vitamin D occurs at serum concentrations ! 40 ng/mL in pregnancy. 10, 11 Wagner et al 7 suggested that in pregnancy, optimal conversion of 25(OH)D to 1,25(OH) 2 D, as well as reduced preterm birth rates among women, was most sig- from an RCT of pregnant women. Our secondary objective was to evaluate if vitamin D supplementation decreased BV incidence in pregnancy. We hypothesized that women with vitamin D deficiency would be more likely to experience BV during pregnancy and women supplemented to a 25(OH)D concentration ! 40 ng/mL would be less likely to experience a new BV episode in pregnancy.
Methods
This study was approved by the Institutional Review Board of the Medical University of South Carolina (Protocol #20570) and all subjects provided written informed consent. This was a preplanned analysis within a larger RCT of 450 pregnant women, 18 to 45 years old with singleton pregnancies, enrolled between 8 and 14 weeks of gestation and followed until delivery between 2013 and 2015 (ClinicalTrials.gov, trial #NCT01932788) (►Fig. 1). Mothers were randomized to receive the standard daily prenatal vitamin (containing 400 IU vitamin D 3 ) AE 4,000 IU vitamin D 3 daily. Subjects were followed up monthly during pregnancy up to a total of nine study visits.
Subjects were excluded from the parent study if they had a preexisting calcium disorder, uncontrolled thyroid or parathyroid disease, requirement for chronic diuretic or cardiac medication therapy including calcium-channel blockers, sickle cell disease, sarcoidosis, or inflammatory bowel disease. A subgroup of $100 subjects with known diabetes, hypertension, or body mass index (BMI) > 49 kg/m 2 did participate but were excluded from analysis in the present study. A sample size of 240 subjects, 120 in each arm, was calculated to be sufficient to detect a clinically important difference of 0.3 between groups in achieving a total circulating 25(OH)D concentration of at least 40 ng/mL assuming a standard deviation of 10 using a two-tailed t-test of difference between means with 80% power and a 5% level of significance. The total sample size was adjusted to 264 (132 per group) giving consideration to a dropout rate of 10%. A stratified block randomization was used to attain equal group numbers and balanced numbers by racial/ethnic group. Adherence to treatment was assessed by monthly pill count and women with an adherence rate of < 60% predicted pill intake for 2 consecutive months exited the study (n ¼ 60: 7 white/Caucasian; 18 Hispanic; and 35 black/African American [AA] women). The parent study was not powered to detect a difference in BV as a clinical outcome. Subjects were included in this current analysis if they had at least one vaginal sample measured for BV (n ¼ 257). In the present study, subjects (n ¼ 13 total) were excluded from the BV analysis if spontaneous abortion (< 20 weeks' gestation) (n ¼ 10) or intrauterine fetal demise (all < 30 weeks) (n ¼ 3) was diagnosed during the pregnancy. From the original cohort, 133 women from the 4,400 IU group and 112 from the control group were included in the current analysis.
Target vitamin D was defined as a plasma 25(OH)D concentration of ! 40 ng/mL based on prior pharmacokinetics studies. 26 
Timing of Vitamin D Supplementation
Subjects from the parent study were randomized to 4,000 IU cholecalciferol versus placebo following enrollment. Thus, baseline measurements at visit 1 were obtained before randomization.
Statistical Analysis
Statistical analyses were performed using SAS 9.4 software (Cary, NC). Binomial data were compared using chi-square and Fischer's exact tests depending on the sample size. The Shapiro-Wilk's analysis was used to evaluate continuous variables for normal distribution. Normally distributed continuous variables were described as means with standard deviation and nonnormally distributed continuous variables were described as medians with a corresponding interquartile range. Continuous variables were analyzed using Student's t-test and Wilcoxon's rank-sum test; categorical variables were analyzed by chi-square and Fisher's exact tests. Mixed logistic regression was created using a forward iterative process to account for repeated measures over time using SAS 9.4 PROC GLIMMIX procedure (Cary, NC) with the primary outcome variable chosen as BV development. BV prevalence over time was modeled by linear mixed effects. Vitamin D concentration (continuous), gestational age, age (continuous), race/ethnicity, and prepregnancy BMI (continuous) were chosen for fixed effects, while subject identification was used as the random effect. Variables included in the model were chosen by significance in univariate analysis at the p < 0.2 threshold. Pregnancy outcomes of interest in the regression model included gestational hypertension, preeclampsia, hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome, chorioamnionitis, and preterm birth.
Results
Among all study subjects, 245 women with at least one vaginal smear available for Gram staining were included in the current analysis. Included subjects having a median age of 29 years were predominantly non-Hispanic white race and had a mean 
Impact of Vitamin D Supplementation on Bacterial Vaginosis Powell et al. e230
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
prepregnancy BMI of 25.9 kg/m 2 . A majority were privately insured and had finished college (►Table 1). Chlamydia was the most common sexually transmitted infection diagnosed in pregnancy (5%), followed by herpes simplex virus. At initial visit (8-13 weeks), the mean 25(OH)D concentration was 26.2 ng/mL (AE9.5 ng/mL), which increased to a mean concentration of 42.4 ng/mL (AE18.6 ng/mL) by delivery. Almost 5% of participants experienced preterm delivery (< 37 weeks' gestation). The second most common complication of pregnancy was preeclampsia (4.1%) (►Fig. 1).
Mean 25(OH)D Concentration by Randomization Group
Study participants in treatment (4,000 þ 400 IU in prenatal vitamin) versus control (400 IU in prenatal vitamin) arm had statistically significantly different 25 
BV Development in Pregnancy
Sixteen women developed BV during pregnancy and were significantly younger than those who did not (26.5 vs. 29 years; p ¼ 0.02). There were no other differences noted in terms of race/ethnicity, prepregnancy BMI, insurance type, education level, or incidence of sexually transmitted infections (►Table 3). There were also no significant differences in mean 25(OH)D concentrations throughout pregnancy or among pregnancy outcomes of interest between women who did and did not develop BV during pregnancy. In univariate analysis, only prepregnancy BMI category was significantly associated (unadjusted odds ratio: 0.72, 95% confidence interval: 1.01-4.2, p ¼ 0.046) with BV development; however, this variable was no longer significant following adjustment for race, age, treatment group, and 25(OH)D concentrations at each time point by multivariate logistic regression. Per cent change in vitamin D concentrations between visits 1 and 4, 4 and 7, and 1 and 7 were calculated and did not significantly correlate with BV prevalence.
Vitamin D Concentration and BV Prevalence
Overall, the relationship between 25(OH)D concentration and BV was not strong or statistically significant. The unadjusted baseline 25(OH)D was significantly associated with BV at visit 1 (p ¼ 0.01) but not with BV development in pregnancy (p ¼ 0.14). Following adjustment for age, race/ethnicity, gestational age, and prepregnancy BMI, this relationship between baseline 25(OH)D and BV was no longer significant. While ►Fig. 3 demonstrates an apparent increase in BV prevalence over time just among AA women, it, however, still showed no significant effect of vitamin D concentration either as a continuous or categorical variable (at 40 or 20 ng/mL levels).
Discussion
In this nested cohort from the Kellogg Pregnancy Study RCT, baseline vitamin D deficiency and vitamin D supplementation did not appear to have a significant impact on incidence or prevalence of BV during pregnancy, after accounting for race/ethnicity, age, and prepregnancy BMI. Consistent with prior reports in the literature, race was an independent, significant predictor for BV. It is reasonable to compare our results with previous studies because there does not appear to be any evidence that BV is more common in pregnancy. Our results are also consistent with the previously published RCT investigating vitamin D supplementation to reduce BV recurrence in nonpregnant women, which showed no significant difference in BV recurrence based on randomized treatment group. Subjects in our study had higher mean plasma 25(OH)D concentrations at trial completion, compared with previous studies. In support of this hypothesis, vitamin D receptor knockout mice have significantly decreased intestinal lactobacilli concentrations. In the human vagina, decreased lactobacilli concentration is associated with vaginal dysbiosis. 33 While not currently known, there may still be a dose-dependent effect of vitamin D on the female genital tract, which may be further affected by race and pregnancy. Additional factors not studied in our RCT may mitigate this effect. Strengths of this study include a relatively large sample size and randomized study design, as well as consistent Nugent score reading by one investigator (A.M.P.). The sample size may not have provided enough power to detect racial differences in BV by 25(OH)D concentration, however. More subtle differences between groups may also not have been detectable by Gram stain or Nugent score assignment. Additional limitations include the possible confounding biological effects of AA race and vitamin D supplementation; however, even after isolating the race variable, no significant effect of vitamin D supplementation on BV prevalence was observed. Clearly, additional studies would be needed to further delineate the role of vitamin D and the impact of supplementation on the female genital tract and its microbiome, and particularly during pregnancy. A matched case-control design could further clarify racial differences and effects of vitamin D supplementation on the incidence of BV.
Conclusion
Vitamin D supplementation did not appear to have a significant impact on incidence or prevalence of BV during pregnancy, even after accounting for race, age, and treatment group assignment.
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This study was presented at the annual Infectious Disease Society for Obstetricians and Gynecologists in Park City, UT, August 2017.
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